Billing and Coding: MolDX: Oncotype DX® Breast Cancer Assay

Oncotype DX Breast is intended for ER-positive invasive breast cancer patients who are node-negative, have nodal micrometastases, or have 1–3 positive lymph nodes. Billing requires entering '1' in Days/Unit, reporting the appropriate ICD-10-CM code, and including the Z-Code Identifier in specified Part A and Part B claim narrative fields; DCIS-related tests and codes are excluded and must not share the same Z-Code.

"Oncotype DX Breast is indicated for patients with estrogen-receptor (ER) positive, node-negative invasive breast carcinoma."

Sign up to see full coverage criteria, indications, and limitations.